<DOC>
	<DOCNO>NCT02305186</DOCNO>
	<brief_summary>The purpose clinical trial study experimental drug call pembrolizumab MK-3475 use combination chemotherapy radiation therapy patient resectable ( surgical removal ) borderline resectable pancreatic cancer . In general , pancreatic cancer remove surgery sometimes treat chemotherapy radiation therapy , call neoadjuvant treatment , shrink tumor surgery might possible . However , always effective shrink tumor enough allow remove surgery . Recent discovery suggest investigator immune system might role control growth tumor . Drugs pembrolizumab stimulate immune system cancer . The purpose study investigate whether pembrolizumab use safely neoadjuvant treatment improve body 's immune response pancreatic cancer . Pembrolizumab approve treatment patient melanoma proven safe helpful patient pancreatic cancer approve U.S. Food Drug Administration ( FDA ) purpose .</brief_summary>
	<brief_title>Safety Immunological Effect Pembrolizumab Resectable Borderline Resectable Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Measurable disease base Response Evaluation Criteria Solid Tumors ( RECIST ) 1 . 2 . Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale 3 . Adequate organ function 4 . In subject require biliary decompression , metal stent drainage use percutaneous transhepatic cholangiogram ( PTC ) allow 1 . Immunodeficiency take steroid form immunosuppressive therapy 2 . Has plastic biliary stent decompression 3 . Metastatic disease 4 . Prior treatment pancreatic cancer prior treatment radiation diagnosis expect pancreatic cancer treatment area 5 . Active autoimmune disease 6 . Pregnancy Nursing 7 . Known history Human Immunodeficiency Virus ( HIV ) Hepatitis B C 8 . Prior monoclonal antibody within 4 week prior study Day 1 9 . Known additional malignancy progress require active treatment 10 . Evidence interstitial lung disease active , noninfectious pneumonitis 11 . Active infection require systemic therapy 12 . Prior therapy antiProgram Death ( PD1 ) antibody , antiPDL1 , antiPDL2 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Resectable</keyword>
	<keyword>Borderline resectable</keyword>
</DOC>